OR WAIT null SECS
There are positive indications for future growth.
Revolutionary therapies restructure pharmaceutical manufacturing.
Single-use technologies provide a barrier between operators and drug products, allowing for sterility and personnel safety in manufacturing.
March 28, 2024
The new Verafit products from STERIS are designed to help manufacturers conform to regulatory requirements laid out in Annex 1.
March 25, 2024
With the Vacaville, Calif., site acquisition, Lonza gains one of the largest biologics manufacturing sites for mammalian cell-based therapeutics.
Webinar Date/Time: Thu, Thu, Apr 18, 2024 11:00 AM EDT
Webinar Date/Time: Thu, Apr 25, 2024 11:00 AM EDT
March 21, 2024
CDMO White Raven aims to reduce contamination risk and gain the capability to handle multiple product formats with the installation of Cytiva’s SA25 Aseptic Filling Workcell.
Webinar Date/Time: Wed, May 8, 2024 11:00 AM EDT
March 20, 2024
AstraZeneca’s acquisition of Amolyt Pharma includes eneboparatide, a Phase III therapeutic peptide for the treatment of hypoparathyroidism.
March 19, 2024
Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel) marks the first gene therapy approved in the US for treating children with metachromatic leukodystrophy.
March 15, 2024
The evolution of therapeutic modalities drives the adoption of single-use technologies.
ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection